My time at Science: Don Kennedy

It was the days before the two competing groups of researchers published the first draft of the human genome (released in February, 2001), and Don Kennedy was stressed out. As editor of Science, he was trying to get both groups to publish simultaneously, and in his journal. In the end, he got his first wish, but not his second. "I told somebody that if we had succeeded in that venture it would have made an issue of Science bigger than the Christmas issue of Vogue," he recalled recently.

Written byAlison McCook
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
It was the days before the two competing groups of researchers published the first draft of the human genome (released in February, 2001), and Don Kennedy was stressed out. As editor of Science, he was trying to get both groups to publish simultaneously, and in his journal. In the end, he got his first wish, but not his second. "I told somebody that if we had succeeded in that venture it would have made an issue of Science bigger than the Christmas issue of Vogue," he recalled recently. "In the end, it may be just as well that we got one and Nature got the other." Now, Kennedy is in the final days of his position at Science (Bruce Alberts linkurl:takes over;http://www.the-scientist.com/blog/display/54026/ March 1), and he spoke with me about his fondest memories of the experience - and those that were less fond (think getting up in California, where he is based, to call into Washington DC meetings scheduled for 9:30 AM). The stress over the human genome papers was difficult, but that's part of what made the experience valuable, he noted. "I think some of the memories which were difficult were ones in which I felt I had more support and thoughtful help and had more gratitude for," he said. Another "fairly dramatic problem" that ultimately proved rewarding for Kennedy was the journal's linkurl:retraction of data;http://www.the-scientist.com/news/display/22933/ from South Korean researcher Woo-Suk Hwang and his colleagues, who admitted to fabricating proof-of-principle research in human embryonic stem cells. "We had to do a lot of self analysis and explanation about that, and I think we've wound up as a result of the experience in a better place than we would have been without it," he said. Of course, much of his time was spent answering angry authors - a lot of time, given that the journal receives 12,000 submissions per year and linkurl:rejects;http://www.the-scientist.com/article/display/23061/ all but about 8%. "There were a fair number of [complaints], but not dramatically more than I expected." Kennedy chalks up much of this angst to more than just rejection letters from Science - the research community is dealing with a host of adverse conditions, he said, most notably a lack of NIH funding, causing rejections of some very good projects. "It's an unhappy moment in history for all kinds of reasons." But for Kennedy, right now things are looking pretty good. Being at Science "has been terrific." Click linkurl:here;http://images.the-scientist.com/supplementary/audio/kennedy_quiet.mp3 to listen to my interview with Kennedy. You can also listen linkurl:here;http://www.the-scientist.com/blog/display/54052/ to Bruce Alberts talk about what he expects from the position.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Genome Modeling and Design: From the Molecular to Genome Scale

Genome Modeling and Design: From the Molecular to Genome Scale

Twist Bio 
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

DNA and pills, conceptual illustration of the relationship between genetics and therapeutic development

Multiplexing PCR Technologies for Biopharmaceutical Research

Thermo Fisher Logo
Discover how to streamline tumor-infiltrating lymphocyte production.

Producing Tumor-infiltrating Lymphocyte Therapeutics

cytiva logo

Products

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA

sartorius-logo

Introducing the iQue 5 HTS Platform: Empowering Scientists  with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

parse_logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

shiftbioscience

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery